BRPI0603074A - forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a - Google Patents

forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a

Info

Publication number
BRPI0603074A
BRPI0603074A BRPI0603074-2A BRPI0603074A BRPI0603074A BR PI0603074 A BRPI0603074 A BR PI0603074A BR PI0603074 A BRPI0603074 A BR PI0603074A BR PI0603074 A BRPI0603074 A BR PI0603074A
Authority
BR
Brazil
Prior art keywords
form iii
preparation
pharmaceutical compositions
compositions containing
crystalline form
Prior art date
Application number
BRPI0603074-2A
Other languages
English (en)
Inventor
Gerard Coquerel
Julie Linol
Jean-Claude Souvie
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of BRPI0603074A publication Critical patent/BRPI0603074A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Abstract

FORMA CRISTALINA III DE AGOMELATINA, UM PROCESSO PARA SUA PREPARAçãO E COMPOSIçõES FARMACêUTICAS CONTENDO-A A presente invenção refere-se à forma cristalina III do composto de fórmula (I): caracterizada por seu diagrama de difração de raio X de pó.
BRPI0603074-2A 2005-08-03 2006-08-03 forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a BRPI0603074A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508276A FR2889521B1 (fr) 2005-08-03 2005-08-03 Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
BRPI0603074A true BRPI0603074A (pt) 2007-08-14

Family

ID=36587257

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0603074-2A BRPI0603074A (pt) 2005-08-03 2006-08-03 forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a

Country Status (36)

Country Link
EP (3) EP1752445A1 (pt)
JP (1) JP4580370B2 (pt)
CN (1) CN100450995C (pt)
AR (1) AR057713A1 (pt)
AU (1) AU2006203336B2 (pt)
BR (1) BRPI0603074A (pt)
CA (1) CA2555117A1 (pt)
CY (1) CY1118637T1 (pt)
DK (1) DK2210872T3 (pt)
EA (1) EA011031B1 (pt)
ES (1) ES2614934T3 (pt)
FR (1) FR2889521B1 (pt)
GE (1) GEP20094576B (pt)
GT (1) GT200600347A (pt)
HK (1) HK1098130A1 (pt)
HR (1) HRP20170095T1 (pt)
HU (1) HUE030506T2 (pt)
JO (1) JO3360B1 (pt)
LT (1) LT2210872T (pt)
MA (1) MA28449B1 (pt)
ME (1) ME02689B (pt)
MX (1) MXPA06008790A (pt)
MY (1) MY142856A (pt)
NO (1) NO337010B1 (pt)
NZ (1) NZ548862A (pt)
PE (1) PE20070213A1 (pt)
PL (1) PL2210872T3 (pt)
PT (1) PT2210872T (pt)
RS (1) RS55499B1 (pt)
SA (1) SA06270253B1 (pt)
SG (1) SG130112A1 (pt)
SI (1) SI2210872T1 (pt)
TW (1) TWI389873B (pt)
UA (1) UA83719C2 (pt)
WO (1) WO2007015003A2 (pt)
ZA (1) ZA200606454B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2934856B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede d'obtention de la forme cristalline v de l'agomelatine
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN102001959B (zh) * 2009-09-01 2014-07-02 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
CN102050755B (zh) * 2009-10-29 2014-11-05 重庆医药工业研究院有限责任公司 阿戈美拉汀的晶型及其制备方法
CN101709036B (zh) * 2009-12-17 2012-07-04 天津药物研究院 阿戈美拉汀中间体2-(7-甲氧基-1-萘基)乙胺的制备
CN101781226B (zh) 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN101774937B (zh) * 2010-02-05 2014-01-08 天津市汉康医药生物技术有限公司 N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺及其组合物
CL2011001405A1 (es) 2010-06-10 2012-03-30 Gador S A Conicet Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
CZ303787B6 (cs) * 2011-01-21 2013-05-02 Zentiva, K.S. Metastabilní krystalové formy agomelatinu a jejich farmaceutické kompozice
CN102690210A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
CN102690209A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
ES2634243T3 (es) 2011-11-30 2017-09-27 Ratiopharm Gmbh Complejo de agomelatina-urea y formas cristalinas del mismo
CZ2012108A3 (en) 2012-02-15 2013-02-27 Zentiva Ks A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine
WO2014096373A1 (en) 2012-12-21 2014-06-26 Laboratorios Lesvi, S. L. Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
PT2810656T (pt) 2013-06-06 2017-11-13 Zentiva As Formulações de agomelatina compreendendo agomelatina na forma de cocristais
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
CZ2013621A3 (cs) 2013-08-13 2015-02-25 Zentiva, K.S. Termodynamicky stabilní tuhý roztok agomelatinu pro použití ve farmaceutické formulaci
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
EP3075724B1 (en) 2015-03-31 2023-07-12 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Solid form of agomelatine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2866336B1 (fr) * 2004-02-13 2006-03-24 Servier Lab Nouveau procede de synthese du (7-methoxy-3,4-dihydro-1-naphtalenyl) acetonitrile et application a la synthese de l'agomelatine

Also Published As

Publication number Publication date
HRP20170095T1 (hr) 2017-03-24
WO2007015003A2 (fr) 2007-02-08
NZ548862A (en) 2008-03-28
PE20070213A1 (es) 2007-05-06
CY1118637T1 (el) 2017-07-12
SI2210872T1 (sl) 2017-03-31
ES2614934T3 (es) 2017-06-02
SG130112A1 (en) 2007-03-20
MY142856A (en) 2011-01-14
ME02689B (me) 2017-10-20
EA011031B1 (ru) 2008-12-30
MXPA06008790A (es) 2008-02-04
UA83719C2 (ru) 2008-08-11
TWI389873B (zh) 2013-03-21
TW200736197A (en) 2007-10-01
RS55499B1 (sr) 2017-05-31
ZA200606454B (en) 2007-12-27
EA200601274A1 (ru) 2007-02-27
NO337010B1 (no) 2015-12-21
EP2210872A1 (fr) 2010-07-28
PL2210872T3 (pl) 2017-07-31
LT2210872T (lt) 2017-01-10
EP1752445A1 (fr) 2007-02-14
JP2007051140A (ja) 2007-03-01
CN1907959A (zh) 2007-02-07
GEP20094576B (en) 2009-01-12
JP4580370B2 (ja) 2010-11-10
DK2210872T3 (en) 2017-02-20
HUE030506T2 (en) 2017-05-29
SA06270253B1 (ar) 2011-05-14
MA28449B1 (fr) 2007-03-01
GT200600347A (es) 2007-02-28
HK1098130A1 (en) 2007-07-13
EP2008993A1 (fr) 2008-12-31
EP2210872B1 (fr) 2016-11-16
WO2007015003A3 (fr) 2007-04-05
JO3360B1 (ar) 2019-03-13
FR2889521B1 (fr) 2007-12-28
NO20063516L (no) 2007-02-05
FR2889521A1 (fr) 2007-02-09
PT2210872T (pt) 2016-12-01
CN100450995C (zh) 2009-01-14
CA2555117A1 (fr) 2007-02-03
AU2006203336B2 (en) 2012-07-12
AR057713A1 (es) 2007-12-12
AU2006203336A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
BRPI0603074A (pt) forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0603059A (pt) forma cristalina v de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0804994A2 (pt) forma cristalina vi de agomelatina, um processo para a sua preparação e composições farmacêuticas contendo-a
BRPI0603043A (pt) forma cristalina iv de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0600795B8 (pt) forma betad-cristalina de cloridrato de ivabradina, um processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
BRPI0604253A (pt) forma deltad-cristalina de cloridrato de ivabradina, um processo para sua preparação e composições farmacêuticas contendo-as
BRPI0600796B8 (pt) forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
BRPI0600696A (pt) forma gamad-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
BRPI0604250A (pt) forma cristalina delta de cloridrato de ivabradina, processo para sua preparação e composições farmacêuticas contendo a mesma
AR053147A1 (es) Forma cristalina del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen
BRPI0500393B8 (pt) forma cristalina ii de agomelatina e sua composição farmacêutica
BRPI0502228A (pt) forma cristalina alfa de ranelato de estrÈncio, processo para sua preparação, e composições farmacêuticas que a contêm
BR112015021443A2 (pt) novo sal de abexinostato, forma cristalina associada, um processo para preparação dos mesmos e composições farmacêuticas contendo-os
BRPI0708278B8 (pt) forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica
EA200900936A1 (ru) Аморфные и кристаллические формы ривастигмина гидротартрата
GEP20094652B (en) New cyrstalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it
CU23678B7 (es) Procedimiento de preparación de la forma cristalina delta del clorhidrato de la ivabradina y las composiciones farmacéuticas que lo contienen
NI200900060A (es) Formas de sal de compuestos de benzotienilo sustituidos

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL